NEWS
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Aeterna Zentaris (NASDAQ: AEZS) has announced the clinical completion of its Phase 3 DETECT-trial, which investigates the efficacy and safety of macimorelin for diagnosing Childhood Onset Growth Hormone Deficiency (CGHD). The trial, which involved 100 pediatric patients in Europe and North America, concluded with the last patient visit on June 13, 2024. The company plans to release top-line data and full study results in Q3 2024. Gilles Gagnon, the CEO, emphasized that the successful completion of this trial marks a significant milestone, potentially expanding the use of macimorelin as a diagnostic tool in pediatric endocrinology.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1095Followers
68Following
7562Visitors
Follow
102256436 : rubbish company